Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
Learn more about:
Related Clinical Trial
Craniopharyngioma With Tumoral Hemorrhage
Neuromodulation for Hypothalamic Obesity
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions
Intranasal Oxytocin in Hypothalamic Obesity
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
Weight Gain in Surgically Treated Adult-onset Craniopharyngioma
Sleep Wake and Melatonin Pattern in Craniopharyngioma
1.5T Intraoperative MR Imaging in Craniopharyngiomas
Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients
A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection
Prospective Study of Children and Adolescents With Craniopharyngioma
Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)